Lyell Immunopharma Announces Promising Phase 1/2 Trial Results for LYL314 in Treating Aggressive Large B-cell Lymphoma, Launches Pivotal PiNACLE Trial

Reuters
06-17
Lyell Immunopharma Announces Promising Phase 1/2 Trial Results for LYL314 in Treating Aggressive Large B-cell Lymphoma, Launches Pivotal PiNACLE Trial

Lyell Immunopharma Inc. has announced positive new clinical data from a multi-center Phase 1/2 trial of its LYL314 treatment for aggressive large B-cell lymphoma. The trial demonstrated an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting. Among those achieving a complete response, 71% remained in complete response for at least six months. The treatment, LYL314, is an autologous dual-targeting CD19/CD20 chimeric antigen receptor $(CAR)$ T-cell product candidate with Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, aimed at relapsed and/or refractory large B-cell lymphoma. A pivotal single-arm PiNACLE trial is currently underway in CAR T-naïve patients. The clinical data will be presented on June 18, 2025, at the International Conference on Malignant Lymphoma in Lugano, Switzerland.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9469888-en) on June 17, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10